Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A serious condition caused by Dengue virus infection. Patients present with an acute febrile illness followed by restlessness, irritability, and bleeding. It may lead to hemorrhagic shock and death.
Biomarker and diagnostic research for Dengue hemorrhagic fever has been reported in the published literature.
9 clinical trials registered, 5 recruiting. Interventions under study include drug therapy, other interventions, and biologic therapy. Pipeline includes 1 PHASE3, 3 PHASE2, 2 NA. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT05611710](https://clinicaltrials.gov/study/NCT05611710) |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 2:54 PM UTC
Common questions about Dengue hemorrhagic fever
Anakinra in Dengue With Hyperinflammation ( AnaDen ) |
PHASE2 |
Oxford University Clinical Research Unit, Vietnam |
UNKNOWN |
[NCT07016321](https://clinicaltrials.gov/study/NCT07016321) | Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative) | PHASE2 | Johns Hopkins University | RECRUITING |
[NCT07007585](https://clinicaltrials.gov/study/NCT07007585) | Risk Factors for Hospitalization and Transfusion Criteria in Patients With Dengue Virus Infection | — | Jose Ivan Rodriguez de Molina Serrano | RECRUITING |
[NCT07002021](https://clinicaltrials.gov/study/NCT07002021) | Effectiveness Evaluation of the "Mosquito-Free Campus" Initiative on Dengue Fever Prevention and Control: A Cluster Randomized Controlled Trial | NA | Sun Yat-sen University | NOT_YET_RECRUITING |
[NCT07409857](https://clinicaltrials.gov/study/NCT07409857) | International Registry of Dengue Infection in Congenital Bleeding Disorders (DengueCBDR) | — | Mahidol University | RECRUITING |
199 publications have been identified in PubMed for Dengue hemorrhagic fever. Kisho has analyzed 153 by research type. Research spans Basic Science / Preclinical (28%), Review / Meta-Analysis (21%), and Case Report / Case Series (20%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 43 | 28% |
Research summaries | 32 | 21% |
Patient case studies | 30 | 20% |
Disease patterns and progression | 26 | 17% |
Testing and diagnosis research | 12 | 8% |
Clinical study results | 7 | 5% |
New treatment approaches | 3 | 2% |
Chowdhury SMMH (2026). [PMID: 41716431](https://pubmed.ncbi.nlm.nih.gov/41716431/). *Health Sci Rep*. [Review / Meta-Analysis]
Saptarini I (2026). [PMID: 42241399](https://pubmed.ncbi.nlm.nih.gov/42241399/). *PLoS One*. [Epidemiology / Natural History]
Khawsang C (2026). [PMID: 41579705](https://pubmed.ncbi.nlm.nih.gov/41579705/). *Biomed Pharmacother*. [Basic Science / Preclinical]
Maynes MA (2026). [PMID: 41915408](https://pubmed.ncbi.nlm.nih.gov/41915408/). *Physiology (Bethesda)*. [Review / Meta-Analysis]
Srikor S (2026). [PMID: 42236711](https://pubmed.ncbi.nlm.nih.gov/42236711/). *Nat Commun*. [Basic Science / Preclinical]
Wang WH (2026). [PMID: 41539348](https://pubmed.ncbi.nlm.nih.gov/41539348/). *Eur J Pharmacol*. [Basic Science / Preclinical]
Flores ME (2026). [PMID: 42083698](https://pubmed.ncbi.nlm.nih.gov/42083698/). *Cureus*. [Case Report / Case Series]
Elenga N (2026). [PMID: 41524649](https://pubmed.ncbi.nlm.nih.gov/41524649/). *Pediatr Blood Cancer*. [Epidemiology / Natural History]
Mahendran R (2026). [PMID: 41360345](https://pubmed.ncbi.nlm.nih.gov/41360345/). *Environ Pollut*. [Diagnostic / Biomarker]
de Barros Cardoso CR (2026). [PMID: 40360744](https://pubmed.ncbi.nlm.nih.gov/40360744/). *Current topics in microbiology and immunology*. [Review / Meta-Analysis]
AI-curated news mentioning Dengue hemorrhagic fever
Updated Jul 24, 2026
A case report highlights the use of immune modulatory therapy for treating severe dengue hemorrhagic fever in a patient with mitochondrial complex I deficiency. This study contributes to understanding potential therapeutic approaches for patients with rare mitochondrial disorders.
The FDA has authorized the CDC DENV-1-4 Real Time RT PCR Assay for detecting dengue virus, enhancing diagnostic capabilities for dengue fever and dengue hemorrhagic fever. This test can be performed with existing laboratory equipment, streamlining the process for public health labs.